Inreq

Tamsulosin Hydrochloride, the active ingredient in Inreq, is an alpha‑1 adrenergic antagonist presented as an oral tablet for oral administration. It is indicated for the treatment of benign prostatic hyperplasia (BPH) and the related lower urinary tract symptoms in adult male patients, helping to improve urinary flow and reduce bladder outlet obstruction.

GNH USA supplies Inreq as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Tamsulosin Hydrochloride acts on the alpha‑1 adrenergic receptors of the prostate and bladder neck, addressing conditions within the benign prostatic hyperplasia (BPH) spectrum.

- Benign prostatic hyperplasia (BPH): reduces smooth muscle tone in the prostate and improves urinary flow. - Lower urinary tract symptoms (LUTS) associated with BPH: alleviates urgency, frequency, and nocturia. - Urinary obstruction due to BPH: facilitates bladder emptying and reduces residual volume. - Prostatic bladder neck dysfunction: relaxes the bladder neck to ease urine passage.

Tamsulosin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Nasal congestion - Abnormal ejaculation (reduced volume or retrograde)

Serious or Rare Side Effects: - Severe hypotension or syncope - Allergic reactions (rash, angioedema) - Priapism (rare prolonged erection)

Before initiating therapy with Tamsulosin, several precautionary measures should be considered to ensure safe use.

- Cardiovascular assessment: evaluate baseline blood pressure and history of orthostatic hypotension. - Hepatic function: use caution in patients with moderate to severe liver impairment. - Concomitant alpha‑blockers: avoid simultaneous use due to additive hypotensive effect. - CYP3A4 inhibitors: monitor for increased drug exposure when strong inhibitors are co‑administered. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Tamsulosin can interact with other medicines, and awareness of these interactions helps manage risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase plasma concentrations. - Other alpha‑adrenergic antagonists (e.g., prazosin, doxazosin): can cause additive hypotension. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil, tadalafil): increase risk of symptomatic hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce tamsulosin efficacy. - Warfarin: potential increase in INR, requiring closer monitoring. - Diuretics: may enhance orthostatic blood pressure changes.